Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is a potent antidiabetic agent with cardiorenal and weight-losing benefits in patients with type 2 diabetes (T2D). The combination of GLP-1 RA with basal insulin has been suggested in several clinical studies as a useful treatment for intensifying...

Full description

Bibliographic Details
Main Authors: Hsuan-Wen Chou, Kai-Pi Cheng, An-Chi Lin, Hao-Chang Hung, Ching-Han Lin, Chih-Chen Wang, Hung-Tsung Wu, Horng-Yih Ou
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceuticals
Subjects:
diabetes
Glucagon-like peptide 1 receptor agonists
glycemic control
insulin
real world study
Online Access:https://www.mdpi.com/1424-8247/15/12/1569

Internet

https://www.mdpi.com/1424-8247/15/12/1569

Similar Items